TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: Patch 1:standard adhesive with own feces in sleeve
Study: NCT01835067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3F8 Gas
Description: Single intravitreal injection of 0.3 mls C3F8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: Single intravitreal injection of 50 micrograms tPA in 0.05 mls

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: Single intravitreal injection of 50 micrograms tPA in 0.05 mls
Study: NCT02746016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula supplemented with Oligosaccharides
Description: sole source nutrition
Study: NCT03179995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be administered in the same fashion as Octreotide
Study: NCT02190084

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurostar repetitive transcranial magnetic stimulator
Description: The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostar repetitive transcranial magnetic stimulator
Description: The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
Study: NCT01541774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Atherectomy System
Description: Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
Study: NCT01717807

Intervention type: OTHER
Intervention: C11-Erlotinib PET/CT
Study: NCT02320149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarecycline
Description: 1.5 mg/kg/day taken orally at the same time each day,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching sarecycline tablets taken orally at the same time each day.
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: Patch 1:standard adhesive with own feces in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: Patch 2:standard adhesive with own feces mixture in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: Patch 2:standard adhesive with own feces mixture in sleeve
Study: NCT00560079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 600mg/day bid for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: Dipyridamole 200mg/day bid for 28 days
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 3
Description: Patch 3: standard adhesive with simulated feces in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 3
Description: Patch 3: standard adhesive with simulated feces in sleeve
Study: NCT00560079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03297996

Intervention type: DIAGNOSTIC_TEST
Intervention: Mobio PowerSoil DNA Isolation Kit
Description: 16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Mobio PowerSoil DNA Isolation Kit
Description: 16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
Study: NCT01390311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 4
Description: Patch 4:standard adhesive with simulated feces mixture in sleeve
Study: NCT01390311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-DLI Salvage Chemotherapy
Description: At the discretion of the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-DLI Salvage Chemotherapy
Description: At the discretion of the treating physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-DLI Salvage Chemotherapy
Description: At the discretion of the treating physician

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Leukocyte Infusion (DLI)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Leukocyte Infusion (DLI)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor Leukocyte Infusion (DLI)
Study: NCT01156311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
Study: NCT00988455

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: 5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
Study: NCT03259854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non invasive mechanical ventilation in pediatrics
Description: use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen mask
Description: use of oxygen mask after successful weaning from invasive mechanical ventilation
Study: NCT00939081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive step recommendation
Description: Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10,000 step/day recommendation
Description: Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
Study: NCT01028365

Intervention type: OTHER
Intervention: No intervention
Description: Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
Study: NCT02118844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 4
Description: Patch 4:standard adhesive with simulated feces mixture in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 5
Description: Patch 5:standard adhesive with buffer in sleeve
Study: NCT02812147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-DOPS
Description: Added as described in the Arm/Group Descriptions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
Study: NCT01741701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03134287

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-finger method, reverse sellick's method
Description: Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-finger method, reverse sellick's method
Description: Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
Study: NCT05590754

Intervention type: DEVICE
Intervention: Hyper-buoyancy Floatation (HBF)
Description: Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment

Intervention type: DEVICE
Intervention: Hyper-buoyancy Floatation (HBF)
Description: Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment

Intervention type: DEVICE
Intervention: Axial Load after 4h of HBF
Description: Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.

Intervention type: DEVICE
Intervention: Axial Load after 4h of HBF
Description: Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
Study: NCT00914524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil tablets, once daily
Study: NCT04431648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY
Description: MRI-guided ultrasound-stimulated microbubble-treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonalleve Focused Ultrasound Device
Description: Sonalleve Focused Ultrasound Device
Study: NCT03271112

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: Measurement of physical performance before and after the 12 wks-exercice program
Study: NCT02069366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
Study: NCT03124433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive oral apalutamide 240mg daily for 12 weeks
Study: NCT01727973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Tab. Doxycycline 50 mg PO per day for 12 weeks
Study: NCT01804374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
Study: NCT00006903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given intramuscularly
Study: NCT01248377

Intervention type: PROCEDURE
Intervention: Skin tests and ELISPOT assay
Description: Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
Study: NCT01907815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor GSK2141795
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01727453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Warfarin in anticoagulant dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparina
Description: Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer.
Study: NCT02041611

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collections
Description: pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
Study: NCT03327649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level transcutaneous vagus nerve stimulation
Description: Stimulation of the auricular branch of the vagus nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low level transcutaneous vagus nerve stimulation
Description: Stimulation of the auricular branch of the vagus nerve
Study: NCT00143403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan + 5 FU + folinic acid
Description: irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid + 5 FU
Description: folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
Study: NCT04270123

Intervention type: OTHER
Intervention: EORTC QLQ-BR45 questionnaire
Description: The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
Study: NCT02351791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 5
Description: Patch 5:standard adhesive with buffer in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6:standard adhesive with buffer mixture in sleeve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6:standard adhesive with buffer mixture in sleeve
Study: NCT04270123

Intervention type: OTHER
Intervention: EORTC QLQ-BR45 questionnaire
Description: The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.

Intervention type: OTHER
Intervention: EORTC QLQ-BR45 questionnaire
Description: The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
Study: NCT04197089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
Study: NCT03530904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization
Description: Early mobilization after CIED implantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization
Description: Early mobilization after CIED implantation
Study: NCT03499223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: 3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5mg
Description: 3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-317 8mg
Description: 3 intravitreal injections of THR-317 8mg, approximately 1 month apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: 3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
Study: NCT02697786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial doppler
Description: Prolonged de airing to decrease the number of MES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial doppler
Description: Prolonged de airing to decrease the number of MES
Study: NCT01120223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Description: Once daily application
Study: NCT00533845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: On-Q Pain Pump
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: On-Q Pain Pump
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Study: NCT00728780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and rosuvastatin
Description: once
Study: NCT03692364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic uncemented hip arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-on-polyethylene uncemented total hip arthroplasty
Study: NCT02769325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: IV atropine 0.1%, 10 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline, 10 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Patients will receive sugamadex for neuromuscular reversion, if necessary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Description: Patients will receive sugamadex for neuromuscular reversion, if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA
Description: Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine PCA
Description: Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
Study: NCT04196309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
Study: NCT03270709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.